Dose-dependent suppression of human glioblastoma xenograft growth by accelerator-based boron neutron capture therapy with simultaneous use of two boron-containing compounds

Research output: Contribution to journalArticlepeer-review

Abstract

(1) Background: Developments in accelerator-based neutron sources moved boron neutron capture therapy (BNCT) to the next phase, where new neutron radiation parameters had to be studied for the treatment of cancers, including brain tumors. We aimed to further improve accelerator-BNCT efficacy by optimizing dosimetry control, beam parameters, and combinations of boronophenylalanine (BPA) and sodium borocaptate (BSH) administration in U87MG xenograftbearing immunodeficient mice with two different tumor locations. (2) Methods: The study included two sets of experiments. In Experiment #1, BPA only and single or double irradiation in higher doses were used, while, in Experiment #2, BPA and BSH combinations and single or double irradiation with dosage adjustment were analyzed. Mice without treatment or irradiation after BPA or BPA+BSH injection were used as controls. (3) Results: Irradiation parameter adjustment and BPA and BSH combination led to 80–83% tumor-growth inhibition index scores, irradiation:BNCT ratios of 1:2, and increases in animal life expectancy from 9 to 107 days. (4) Conclusions: Adjustments in dosimetry control, calculation of irradiation doses, and combined use of two10B compounds allowed for BNCT optimization that will be useful in the development of clinical-trial protocols for accelerator-based BNCT.

Original languageEnglish
Article number1124
JournalBiology
Volume10
Issue number11
DOIs
Publication statusPublished - Nov 2021

Keywords

  • Accelerator-based neutron source
  • Animal tumor model
  • Boron compounds
  • Boron neutron capture therapy
  • Boronophenylalanine
  • Glioblastoma
  • Sodium borocaptate

OECD FOS+WOS

  • 1.06.CQ BIOCHEMISTRY & MOLECULAR BIOLOGY

Fingerprint

Dive into the research topics of 'Dose-dependent suppression of human glioblastoma xenograft growth by accelerator-based boron neutron capture therapy with simultaneous use of two boron-containing compounds'. Together they form a unique fingerprint.

Cite this